MEKanistic Clears FDA IND for MTX-531 Cancer Trial
MINNEAPOLIS, Minn., May 19, 2026 MEKanistic Therapeutics has announced that the U.S. Food and Drug Administration (FDA) cleared the...
lung cancer
Advertisement
Bayer’s Sevabertinib Gets FDA Priority Review
BERLIN, Germany, May 18, 2026 Bayer has announced that the U.S. Food and Drug Administration (FDA) granted Priority Review...
Genentech Highlights Giredestrant Data at ASCO 2026
SOUTH SAN FRANCISCO, Calif., May 18, 2026 Genentech, a member of the Roche Group, announced that it will present...
Nuvation Bio Expands IBTROZI FDA Lung Cancer Filing
NEW YORK, May 6, 2026 Nuvation Bio Inc., a global oncology-focused biopharmaceutical company, has announced that the U.S. Food...
Nuvalent ALKOVE-1 Data Boosts NSCLC Targeted Therapy
Cambridge, Massachusetts, USA, April 21, 2026 In a major advancement for targeted cancer therapy, Nuvalent, Inc. has announced the...
Advertisements
Revolution Medicines Reports Breakthrough Zoldonrasib Data
REDWOOD CITY, Calif., April 19, 2026 A major breakthrough in targeted oncology therapy has emerged as Revolution Medicines unveiled...
MAIA Activates U.S. Site for Phase 2 Lung Cancer Trial
CHICAGO, April 16, 2026 MAIA Biotechnology, Inc. has announced the activation of its first U.S. clinical site for the...
Boehringer Ingelheim Zongertinib Shows Strong NSCLC Results
INGELHEIM, Germany, April 16, 2026 Boehringer Ingelheim has announced the publication of Phase 1b Beamion LUNG-1 trial results for...
Geminii Shows Promising NSCLC Data for Bioelectronic Therapy
CHICAGO, April 16, 2026 Geminii, Inc. has announced the presentation of new preclinical data on its bioelectronic therapy platform...
Adagene Reports Strong Muzastotug KEYTRUDA CRC Data
San Diego, USA & Suzhou, China, April 2, 2026 Strong Clinical Efficacy in MSS Colorectal Cancer In a major...
Advertisement
